Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta And Hepatitis B Programs At AASLD's The Liver Meeting 2024
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta And Hepatitis B Programs At AASLD's The Liver Meeting 2024
These data will be presented in an oral presentation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, in San Diego, CA, November 15-19, 2024. Vir will also present five poster presentations that further characterize these investigational therapies as well as recent efforts to improve the assessment and evaluation of hepatitis delta infection, and insights into the economic burden of hepatitis delta for patients and society. Vir will also share advances from across the chronic hepatitis B development program.– Phase 2 SOLSTICE Safety and Efficacy Data in Hepatitis Delta Trial at Week 24 to Be Presented –
– 第2阶段 SOLSTICE 肝炎 Delta 试验在第24周的安全性和有效性数据将被提出 –
– Oral and Five Poster Presentations Highlight Important Progress in Hepatitis Delta and Hepatitis B Clinical Programs, and Deliver Key Insights on the Burden of Disease Among Patient Segments in Hepatitis Delta –
– 口头报告和五个海报展示在肝炎 Delta 和肝炎 b 临床计划取得的重要进展，并就各患者群体中肝炎 Delta 疾病负担提供关键见解 –
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will present new data from the Phase 2 SOLSTICE clinical trial evaluating the efficacy and safety profile of tobevibart, an investigational monoclonal antibody (mAb), and elebsiran, an investigational small interfering ribonucleic acid (siRNA) for the potential treatment of chronic hepatitis delta.
Vir生物科技公司（纳斯达克：VIR）今天宣布将展示Phase 2 SOLSTICE临床试验的新数据，评估tovebivart单克隆抗体（mAb）和elebsiran小干涉核糖核酸（siRNA）的疗效和安全性，以潜在治疗慢性肝炎 Delta。
These data will be presented in an oral presentation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, in San Diego, CA, November 15-19, 2024. Vir will also present five poster presentations that further characterize these investigational therapies as well as recent efforts to improve the assessment and evaluation of hepatitis delta infection, and insights into the economic burden of hepatitis delta for patients and society. Vir will also share advances from across the chronic hepatitis B development program.
这些数据将在即将举行的美国肝病研究协会（AASLD）肝脏年会口头报告中发布，时间地点：2024年11月15日至19日，地点：加利福尼亚州圣地亚哥。Vir还将展示五个海报，进一步描述这些调查疗法以及最近努力改善肝炎 Delta 感染的评估和评价，以及关于肝炎 Delta 对患者和社会的经济负担的见解。Vir还将分享整个慢性肝炎 b 发展计划的最新进展。
